MTOR and melanoma: As previously reported by our group, SN-MM are characterized by recurrent expression of phosphorylated Akt on melanoma cells from clinical samples, suggesting a relevant role for the activation of the PI3K-Akt-mTOR pathway in these neoplasms [16].